Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Sophie Godet; Caroline Protin; Jehan Dupuis; Caroline Dartigeas; Jean‐Noël Bastie; Charles Herbaux; Véronique Leblond; Sophie de Guibert; David Ghez; Annie Brion; Loïc Ysebaert; Alain Delmer; Anne Quinquenel

+ Author Information

Author Information: CHU Reims, Hôpital Robert Debré, Service d'Hématologie Clinique


		Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


		Loading Related Articles

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Abstract

Related Topics